WebbIn conclusion, HIPEC using MMC-5FU was shown to be a feasible therapeutic option, with an acceptable toxicity profile, for patients at high risk of PM from CRC. Therefore, … WebbMMC or Oxali based HIPEC chemotherapy are both safe and effective for the management of peritoneal only metastatic CRC. Both perfusion therapies should be considered with …
Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC …
WebbBetween October 2006 and September 2009, 187 patients with PC from appendiceal or colorectal origins were treated with CRS and HIPEC. Fifty-five patients (29.4%) had oxaliplatin-based HIPEC while 132 patients (70.6%) received MMC-based HIPEC. Characteristics of the 187 cases as a function of HIPEC agent used are presented in … Webb23 mars 2024 · Introduction: Over the past two decades, cytoreductive surgery and HIPEC has improved outcomes for selected patients with peritoneal metastasis from various origins. This is a cross-sectional study with descriptive analyses of HIPEC trials registered on ClinicalTrials.gov. This study aimed to characterize clinical trials on HIPEC … thoroughly written
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for
WebbBackground Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with favorable short- and long-term oncological outcomes in highly selected patients with peritoneal metastasis (PM). The aim of our review was to review published, recruiting or ongoing randomized controlled trials (RCTs) evaluating CRS … Webb中国肿瘤临床 2015年第42卷第4期Chin J Clin Oncol 2015,Vol.42,N细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识李雁周云峰梁寒王华庆郝继辉朱正纲万德森钦伦秀崔书中季加孚徐惠绵魏少忠许洪斌锁涛杨树军谢丛 Webb1 maj 2001 · MMC toxicity existed mainly of leucocytopenia (in 15 patients; 52%). After a median follow-up of 38 months (range 26–52 months) we found a 2- and 3-year survival rate (Kaplan–Meier) of 45 and 23%, respectively. Extensive cytoreductive surgery and HIPEC is feasible in patients with peritoneal seeding of colorectal cancer. thoroughly work